A multicenter clinical trial of DCVax-L, a personalized vaccine that targets the aggressive brain cancer glioblastoma, has indicated improved patient survival rates. The results appear in the Journal of Translational Medicine. A personalized vaccine targeting glioblastoma may improve survival for some patients. Image credit: Angelo Esslinger. Personalized vaccines are specifically tailored to individual patients. The clinical trial included 331 patients...
